Abstract
Antisense oligonucleotides (AS-ODNs) are short, single-stranded DNA molecules designed to bind specifically to a target messenger RNA (mRNA) and down-regulate gene expression. Despite being a promising class of therapeutics for a variety of diseases, they face major hurdles limiting their clinical application, including low intracellular delivery and poor in vivo stability. Among strategies available to enhance delivery, lipid nanoparticles have gained considerable attention. Active targeting of carriers of AS-ODNs is likely to further enhance delivery efficiency. For that, ligands for overexpressed receptors on the cell surface can be linked to the lipid nanoparticle, facilitating intracellular uptake, resulting in improved efficacy and reduced systemic toxicity. These include cell penetrating peptides (CPPs), transferrin, folate, oligosaccharides, polysaccharides and antibodies. Although targeted-lipid nanoparticles have been shown to enhance intracellular delivery and therapeutic effect of AS-ODNs, no clinical evaluation has been conducted yet. Therefore, more efforts are needed to turn these promising tools into clinical products.
Keywords: Antisense oligonucleotides, liposomes, nanoparticles, targeting.
Current Pharmaceutical Biotechnology
Title:Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Volume: 15 Issue: 9
Author(s): Raquel Petrilli, Josimar O. Eloy, Juliana M. Marchetti, Renata F.V. Lopez and Robert J. Lee
Affiliation:
Keywords: Antisense oligonucleotides, liposomes, nanoparticles, targeting.
Abstract: Antisense oligonucleotides (AS-ODNs) are short, single-stranded DNA molecules designed to bind specifically to a target messenger RNA (mRNA) and down-regulate gene expression. Despite being a promising class of therapeutics for a variety of diseases, they face major hurdles limiting their clinical application, including low intracellular delivery and poor in vivo stability. Among strategies available to enhance delivery, lipid nanoparticles have gained considerable attention. Active targeting of carriers of AS-ODNs is likely to further enhance delivery efficiency. For that, ligands for overexpressed receptors on the cell surface can be linked to the lipid nanoparticle, facilitating intracellular uptake, resulting in improved efficacy and reduced systemic toxicity. These include cell penetrating peptides (CPPs), transferrin, folate, oligosaccharides, polysaccharides and antibodies. Although targeted-lipid nanoparticles have been shown to enhance intracellular delivery and therapeutic effect of AS-ODNs, no clinical evaluation has been conducted yet. Therefore, more efforts are needed to turn these promising tools into clinical products.
Export Options
About this article
Cite this article as:
Petrilli Raquel, Eloy O. Josimar, Marchetti M. Juliana, Lopez F.V. Renata and Lee J. Robert, Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery, Current Pharmaceutical Biotechnology 2014; 15 (9) . https://dx.doi.org/10.2174/1389201015666141020155834
DOI https://dx.doi.org/10.2174/1389201015666141020155834 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Novel Tetradentate Ruthenium(II) Complex Containing Tris(2- pyridylmethyl)amine (tpa) as an Inhibitor of Beta-Amyloid Fibrillation
Current Alzheimer Research CDK9 a Potential Target for Drug Development
Medicinal Chemistry Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology New Anti-Mitotic Drugs with Distinct Anti-Calmodulin Activity
Mini-Reviews in Medicinal Chemistry The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Playing Modular Puzzle with Adhesion/Growth-Regulatory Galectins: Design and Testing of a Hybrid to Unravel Structure-Activity Relationships
Protein & Peptide Letters Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design The Targets of Curcumin
Current Drug Targets Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Prediction and Targeting of Interaction Interfaces in G-protein Coupled Receptor Oligomers
Current Topics in Medicinal Chemistry Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Biological Targets of Antitumor Indolocarbazoles Bearing a Sugar Moiety
Current Medicinal Chemistry - Anti-Cancer Agents A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology